ATE545657T1 - Tgf-beta antikörper - Google Patents

Tgf-beta antikörper

Info

Publication number
ATE545657T1
ATE545657T1 AT06840328T AT06840328T ATE545657T1 AT E545657 T1 ATE545657 T1 AT E545657T1 AT 06840328 T AT06840328 T AT 06840328T AT 06840328 T AT06840328 T AT 06840328T AT E545657 T1 ATE545657 T1 AT E545657T1
Authority
AT
Austria
Prior art keywords
tgf
beta antibodies
antibodies
mammal
antigen
Prior art date
Application number
AT06840328T
Other languages
English (en)
Inventor
Bryan Jones
James Pancook
Scott Rowlinson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE545657T1 publication Critical patent/ATE545657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06840328T 2005-12-23 2006-12-20 Tgf-beta antikörper ATE545657T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75395605P 2005-12-23 2005-12-23
PCT/US2006/062397 WO2007076391A1 (en) 2005-12-23 2006-12-20 Tgf-beta binding compositions

Publications (1)

Publication Number Publication Date
ATE545657T1 true ATE545657T1 (de) 2012-03-15

Family

ID=37898733

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06840328T ATE545657T1 (de) 2005-12-23 2006-12-20 Tgf-beta antikörper

Country Status (10)

Country Link
US (3) US7494651B2 (de)
EP (1) EP1966243B1 (de)
JP (1) JP2009521496A (de)
CN (1) CN101346394B (de)
AT (1) ATE545657T1 (de)
AU (1) AU2006330542B2 (de)
BR (1) BRPI0620240A2 (de)
CA (1) CA2632799A1 (de)
ES (1) ES2379194T3 (de)
WO (1) WO2007076391A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740615B1 (de) * 2004-03-31 2014-11-05 Genentech, Inc. Humanisierte anti-tgf-beta-antikörper
EP1966243B1 (de) * 2005-12-23 2012-02-15 Eli Lilly And Company Tgf-beta antikörper
US8350006B2 (en) * 2008-10-24 2013-01-08 Mead Johnson Nutrition Company Methods for determining the bioactivity of TGF-β in a composition
JP5818688B2 (ja) * 2009-01-08 2015-11-18 バイオ−ラッド ラボラトリーズ インコーポレーティッド 核酸増幅反応の効率を改善するための方法および組成物
WO2010124276A2 (en) * 2009-04-24 2010-10-28 Vanderbilt Universtiy Anti-tgf-beta induction of bone cell function and bone growth
CN103732623B (zh) * 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
CA2866378A1 (en) 2012-03-08 2013-09-12 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
HRP20181939T4 (hr) * 2013-03-20 2022-05-13 Genzyme Corporation Postupci za liječenje osteogenesis imperfecta
WO2016024628A1 (ja) * 2014-08-14 2016-02-18 学校法人東京医科大学 樹状細胞の抗癌免疫賦活能の促進方法およびその用途
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
EP3770171A1 (de) 2015-04-03 2021-01-27 XOMA Technology Ltd. Behandlung von krebs unter verwendung von inhibitoren von tgf-beta und pd-1
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
AU2017268234A1 (en) 2016-05-17 2018-12-13 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
WO2018128939A1 (en) 2017-01-05 2018-07-12 Gensun Biopharma Inc. Checkpoint regulator antagonists
TWI832600B (zh) * 2017-01-20 2024-02-11 美商健臻公司 骨靶向抗體
TW201923089A (zh) 2017-11-06 2019-06-16 美商建南德克公司 癌症之診斷及治療方法
US10597453B2 (en) 2018-06-29 2020-03-24 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
CN113613725B (zh) 2018-11-05 2025-09-23 路德维格癌症研究所有限公司 人源化和变体TGF-β1特异性抗体及其方法和用途
EP3877053A1 (de) 2018-11-05 2021-09-15 Ludwig Institute for Cancer Research Ltd Humanisierte und variante tgf-beta3-spezifische antikörper sowie verfahren und verwendungen davon
CN114340735B (zh) 2019-06-28 2024-11-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
AU2020322474A1 (en) 2019-08-01 2022-03-10 Vaccinex,Inc. Combined inhibition of semaphorin-4D and TGFβ and compositions therefor
WO2021167703A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
US20240002479A1 (en) * 2020-11-23 2024-01-04 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
EP4251645A1 (de) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Mit signalmodulatoren manipulierte zelluläre therapeutika und verfahren zur verwendung davon
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN119213034A (zh) 2022-05-17 2024-12-27 苏州创胜医药集团有限公司 双功能蛋白质及其制剂和用途
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
EP4599088A1 (de) 2022-10-05 2025-08-13 Genentech, Inc. Verfahren und zusammensetzungen zur klassifizierung und behandlung von lungenkrebs
TW202434643A (zh) * 2023-01-09 2024-09-01 大陸商北京拓界生物醫藥科技有限公司 ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
EP1740615B1 (de) * 2004-03-31 2014-11-05 Genentech, Inc. Humanisierte anti-tgf-beta-antikörper
EP1966243B1 (de) * 2005-12-23 2012-02-15 Eli Lilly And Company Tgf-beta antikörper

Also Published As

Publication number Publication date
AU2006330542B2 (en) 2012-05-24
US20090155285A1 (en) 2009-06-18
EP1966243B1 (de) 2012-02-15
AU2006330542A1 (en) 2007-07-05
BRPI0620240A2 (pt) 2011-11-08
EP1966243A1 (de) 2008-09-10
US20100136021A1 (en) 2010-06-03
US7494651B2 (en) 2009-02-24
CN101346394B (zh) 2012-07-25
US7927593B2 (en) 2011-04-19
CA2632799A1 (en) 2007-07-05
WO2007076391A1 (en) 2007-07-05
CN101346394A (zh) 2009-01-14
JP2009521496A (ja) 2009-06-04
WO2007076391A9 (en) 2008-08-28
ES2379194T3 (es) 2012-04-23
US20080292638A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
ATE545657T1 (de) Tgf-beta antikörper
NO20082905L (no) Anti-IL-17 antistoff
IL185754A0 (en) Novel anti-plgf antibody
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
EA200802168A1 (ru) Гуманизированное антитело к с-kit
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
NO2017032I1 (no) bezlotoksumab
UA92504C2 (en) Anti-myostatin monoclonal antibody
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
WO2006118772A3 (en) Fcrn antibodies and uses thereof
ATE461220T1 (de) Anti-egfr-antikörper
DK1706424T3 (da) FC-region varianter
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
WO2006074397A3 (en) Cripto binding molecules
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
TW200603828A (en) Treatment of disorders
WO2008085878A3 (en) High affinity antibodies that neutralize staphylcoccus enterotoxin b
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
AU2006278260A8 (en) Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
IL177825A0 (en) Natural igm antibodies and inhibitors thereof
TW200738236A (en) Certain chemical entities, compositions, and methods